Skip to main content
SpringerPlus

Table 2 Selected demographic and baseline characteristics of the patients

From: Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Categorical factor

No dose reduction (N=74)

Dose reduction (N=49)

p-value1

 

N(row%)

N(row%)

 

Her2

   

Negative

64 (63)

38 (37)

0.23

Positive

10 (48)

11 (52)

 

Agent

   

Paclitaxel only

28 (61)

18 (39)

0.572

Docetaxel only

45 (64)

25 (36)

 

Multiple agents3

1 (14)

6 (86)

0.023

Alcohol

   

No

71 (60)

47 (40)

1.00

Yes

3 (60)

2 (40)

 

Diabetes

   

No

67 (65)

36 (35)

0.02

Yes

7 (35)

13 (65)

 

Race

   

Black

40 (57)

30 (43)

0.574

White

30 (63)

18 (37)

 

Other

4 (80)

1 (20)

 

Continuous factor

Mean (range)

Mean (range)

 

Age (years)

53 (32–78)

55 (35–75)

0.23

  1. 1p- values calculated with the use of two-sided Fisher’s and Fisher-Freeman-Halton’s tests for categorical variables and the t-test for continuous variables.
  2. 2Patients treated with paclitaxel (or nab- paclitaxel) only vs. those treated with docetaxel only.
  3. 3Patients treated with multiple agents, compared to those treated with either paclitaxel only or docetaxel only.
  4. 4Black compared to white only.
Back to article page